Medicina
Facultad
Instituto de Química Médica
Madrid, EspañaPublicacións en colaboración con investigadores/as de Instituto de Química Médica (54)
2023
-
Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure-Activity Relationship
ACS Medicinal Chemistry Letters, Vol. 14, Núm. 1, pp. 18-25
2022
-
Editorial: Cannabinoids as potential treatment for neurological diseases
Frontiers in Neuroscience
-
Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades
Journal of Medicinal Chemistry, Vol. 65, Núm. 6, pp. 4727-4751
2021
-
DD04107-Derived neuronal exocytosis inhibitor peptides: Evidences for synaptotagmin-1 as a putative target
Bioorganic Chemistry, Vol. 115
-
Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis
Molecules, Vol. 26, Núm. 24
-
Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis
European Journal of Medicinal Chemistry, Vol. 210
2020
-
Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties
European Journal of Medicinal Chemistry, Vol. 190
2019
-
Fluoroscopic characterization of colonic dysmotility associated to opioid and cannabinoid agonists in conscious rats
Journal of Neurogastroenterology and Motility, Vol. 25, Núm. 2, pp. 300-315
-
Increased expression of cannabinoid CB2 and serotonin 5-HT1A heteroreceptor complexes in a model of newborn hypoxic-ischemic brain damage
Neuropharmacology, Vol. 152, pp. 58-66
-
New flavonoid–N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 34, Núm. 1, pp. 712-727
2018
-
Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease
European Journal of Medicinal Chemistry, Vol. 156, pp. 534-553
-
Preclinical evaluation of the effects on the gastrointestinal tract of the antineoplastic drug vincristine repeatedly administered to rats
Neurogastroenterology and Motility, Vol. 30, Núm. 11
2017
-
Caracterización fluoroscópica en rata de la dismotilidad colónica asociada a tratamiento con morfina
Revista de la Sociedad Espanola del Dolor
-
Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. (2016) 110(2016) (205–215)] (S1043661816302080) (10.1016/j.phrs.2016.03.021)
Pharmacological Research
-
Involvement of cannabinoid signaling in vincristine-induced gastrointestinal dysmotility in the rat
Frontiers in Pharmacology, Vol. 8, Núm. FEB
-
May cannabinoids prevent the development of chemotherapy-induced diarrhea and intestinal mucositis? Experimental study in the rat
Neurogastroenterology and Motility, Vol. 29, Núm. 3
-
New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking
European Journal of Medicinal Chemistry, Vol. 127, pp. 398-412
-
Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases
Journal of Medicinal Chemistry, Vol. 60, Núm. 12, pp. 4983-5001
-
The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro
Scientific Reports, Vol. 7, Núm. 1
2016
-
Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile
Pharmacological Research, Vol. 110, pp. 205-215